92 related articles for article (PubMed ID: 15083598)
21. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
[TBL] [Abstract][Full Text] [Related]
22. New antiplatelet agents for acute coronary syndromes.
Ferguson JJ; Lau TK
Am Heart J; 1998 May; 135(5 Pt 2 Su):S194-200. PubMed ID: 9588400
[No Abstract] [Full Text] [Related]
23. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis.
Dasgupta H; Blankenship JC; Wood GC; Frey CM; Demko SL; Menapace FJ
Am Heart J; 2000 Aug; 140(2):206-11. PubMed ID: 10925331
[TBL] [Abstract][Full Text] [Related]
24. Clinical trials of IIb/IIIa receptor blockers in patients undergoing angioplasty.
Mathew TP; Adgey AA
Semin Interv Cardiol; 1999 Jun; 4(2):67-75. PubMed ID: 10473875
[TBL] [Abstract][Full Text] [Related]
25. Glycoprotein IIb-IIIa antagonists in percutaneous coronary interventions and acute coronary syndromes.
Ramanathan A; Kleiman NS
Indian Heart J; 1998 Oct; 50 Suppl 1():45-56. PubMed ID: 9824907
[No Abstract] [Full Text] [Related]
26. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
Hobbach HP; Schuster P
Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
[TBL] [Abstract][Full Text] [Related]
27. Real-world safety and efficacy of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
Casterella PJ; Revenaugh JR; Burke JL; Pearson RR; Bair TL; May HT; Horne B; Anderson JL; Muhlestein JB
J Invasive Cardiol; 2008 Mar; 20(3):94-8. PubMed ID: 18316822
[TBL] [Abstract][Full Text] [Related]
28. Glycoprotein IIb/IIIa receptor antagonists for the treatment of unstable angina.
Steinhubl SR; Moliterno DJ
Heart Vessels; 1997; Suppl 12():148-55. PubMed ID: 9476567
[TBL] [Abstract][Full Text] [Related]
29. The complementary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention.
Mayes CE; Kandzari DE; Goldschmidt-Clermont PJ; Phillips HR
J Invasive Cardiol; 2002 Dec; 14 Suppl E():36E-46E; quiz 47E. PubMed ID: 12668861
[TBL] [Abstract][Full Text] [Related]
30. Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention.
Januzzi JL; Cannon CP; Theroux P; Boden WE
Am Heart J; 2003 Nov; 146(5):764-74. PubMed ID: 14597924
[TBL] [Abstract][Full Text] [Related]
31. [Inhibitors of GPIIb/IIIa platelet receptors].
Chanu B
Arch Mal Coeur Vaiss; 1999 Jul; 92(7):893-902. PubMed ID: 10443310
[TBL] [Abstract][Full Text] [Related]
32. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).
Tricoci P; Peterson ED; Chen AY; Newby LK; Harrington RA; Greenbaum AB; Cannon CP; Gibson CM; Hoekstra JW; Pollack CV; Ohman EM; Gibler WB; Roe MT
Am J Cardiol; 2007 May; 99(10):1389-93. PubMed ID: 17493466
[TBL] [Abstract][Full Text] [Related]
33. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
[TBL] [Abstract][Full Text] [Related]
34. [Clinical use of glycoprotein IIb/IIIa inhibitors].
Simonetti I; Gallopin M; Gensini GF
Ann Ital Med Int; 1998; 13(3):163-8. PubMed ID: 9859573
[TBL] [Abstract][Full Text] [Related]
35. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
Lincoff AM; Topol EJ
Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004
[No Abstract] [Full Text] [Related]
36. Advances in antiplatelet therapy for acute coronary syndromes.
Clem JR; Falls S
S D J Med; 1998 Jul; 51(7):233-4. PubMed ID: 9676157
[No Abstract] [Full Text] [Related]
37. Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study.
Di Pasquale P; Sarullo FM; Cannizzaro S; Vitrano MG; Giubilato A; Scalzo S; Giambanco F; Paterna S
Ital Heart J; 2001 Oct; 2(10):751-6. PubMed ID: 11721719
[TBL] [Abstract][Full Text] [Related]
38. Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection.
Atwater BD; Roe MT; Mahaffey KW
Drugs; 2005; 65(3):313-24. PubMed ID: 15669877
[TBL] [Abstract][Full Text] [Related]
39. [Glycoprotein IIb/IIIa platelet blockers in acute myocardial infarct treated with primary coronary angioplasty].
Kala P; Poloczek M; Bocek O; Jerábek P; Neugebauer P; Kosová J; Semrád B
Vnitr Lek; 2002 Aug; 48(8):736-41. PubMed ID: 12425204
[TBL] [Abstract][Full Text] [Related]
40. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR
Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
